Insulet (PODD) Tops Q3 EPS by 4c; Boosts FY16 Revenue Outlook

Insulet (NASDAQ: PODD) reported Q3 EPS of ($0.05), $0.04 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $94.9 million versus the consensus estimate of $89.75 million.

GUIDANCE:

Insulet sees FY2016 revenue of $362-365 million, versus prior guidance of $345-355 million and the consensus of $351.5 million.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Fox upgraded to overweight as Roku deal, ad strength lift outlook